New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
NCT ID NCT04205409
Summary
This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or multiple myeloma that have relapsed or are refractory. Participants receive nivolumab by IV infusion every 28 days to see if it helps the immune system fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.